medigraphic.com
ISSN 1817-5996 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cub de Reu 2022; 24 (1)

Two ocular manifestations of Rheumatoid Arthritis: episcleritis and scleritis

Anda AFX, Atiencia MHH, Gómez GML, Sánchez VLS

Language: Spanish
References: 26
Page:
PDF size: 355.92 Kb.


ABSTRACT

Rheumatoid arthritis is a systemic inflammatory disorder that affects the joints, which can have several extra-articular manifestations, including inflammatory eye disease. To provide an overview of the diagnosis and treatment of two ocular manifestations of rheumatoid arthritis: episcleritis and scleritis, including an update on treatment prospects. Ocular manifestations, including episcleritis, scleritis, peripheral ulcerative keratitis, and dry eye disease, can be found in up to 39% of rheumatoid arthritis patients. Although there is no consensus or guidelines, many options issued from rheumatology practice will be available for the treatment of refractory scleritis, once the infectious causes have been ruled out, allowing rapid control of inflammation, and avoiding both structural damage to the eye and complications from long-term steroid use.


REFERENCES

  1. Vignesh APP, Srinivasan R. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies. Clin Ophthalmol. 2015 [Acceso 28/07/2021];9:393-7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348132/

  2. Itty S, Pulido JS, Bakri SJ, Baratz KH, Matteson EL, Hodge DO. Anti-Cyclic Citrullinated Peptide, Rheumatoid Factor, and Ocular Symptoms Typical of Rheumatoid Arthritis. Trans. Am Ophthalmol Soc. 2008 [Acceso 28/07/2021];106:75-81. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646447/

  3. Caimmi C, Crowson CS, Smith WM, Matteson EL, Makol A. Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era. J Rheumatol. 2018 [Acceso 28/07/2021];45(5):595-603. Disponible en: https://www.jrheum.org/content/jrheum/45/5/595.full.pdf

  4. Watson PG, Hayreh SS. Scleritis and episcleritis. Br. J. Ophthalmol. 1976 [Acceso 28/07/2021];60:163-91. Disponible en: https://bjo.bmj.com/content/bjophthalmol/60/3/163.full.pdf

  5. Lavric A, Gonzalez-Lopez JJ, Majumder PD, Bansal N, Biswas J, Pavesio C, et al. Posterior Scleritis: Analysis of Epidemiology, Clinical Factors, and Risk of Recurrence in a Cohort of 114 Patients. Ocul Immunol Inflamm. 2016;24:6-15. DOI: https://doi.org/10.3109/09273948.2015.1005240

  6. Canamary AM, Takahashi WY, Sallum JMF. Autoimmune retinopathy: A Review. Int J Retin Vitr. 2018;4(1). DOI: https://doi.org/10.1186/s40942-017-0104-9

  7. Yoshida A, Watanabe M, Okubo A, Kawashima H. Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis). J Ophthalmol. 2019 [Acceso 28/07/2021];63:417-24. Disponible en: https://link.springer.com/article/10.1007/s10384-019-00674-7

  8. Latif EA, Seleet MM, Hennawi H, Rashed MA, Elbarbary H, Sabry K, et al. Pattern of Scleritis in an Egyptian Cohort. Ocul Immunol Inflamm. 2019;27:890-6. DOI: https://doi.org/10.1080/09273948.2018.1544372

  9. Yang P, Ye Z, Tang J, Du L, Zhou Q, Qi J, et al. Clinical Features and Complications of Scleritis in Chinese Patients. Ocul Immunol Inflamm. 2018;26:387-96. DOI: https://doi.org/10.1080/09273948.2016.1241282

  10. Ryu SJ, Kang MH, Seong M, Cho H, Shin YU. Anterior scleritis following intravitreal injections in a patient with rheumatoid arthritis: A case report. Medicine. 2017 [Acceso 28/07/2021];96:e8925. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5709030/

  11. Díaz-Valle D, Sánchez RM, Espartero MF, Allen DP. Treatment of refractory anterior diffuse scleritis with infliximab. Arch Soc Esp Oftalmol. 2004;79:405-8. DOI: https://doi.org/10.4321/s0365-66912004000800010

  12. Lawuyi LE, Gurbaxani A. Refractory necrotizing scleritis successfully treated with adalimumab. J Ophthalmic Inflamm Infect. 2016 [Acceso 28/07/2021];6(37). Disponible en: https://link.springer.com/article/10.1186/s12348-016-0107-y

  13. Tlucek PS, Stone DU. Certolizumab Pegol Therapy for Rheumatoid Arthritis-Associated Scleritis. Cornea. 2012 [Acceso 28/07/2021];31:90-1. Disponible en: https://journals.lww.com/corneajrnl/Abstract/2012/01000/Certolizumab_Pegol_Therapy_for_Rheumatoid.18.aspx

  14. Durrani K, Kempen JH, Ying G-S, Kacmaz RO, Artornsombudh P, Rosenbaum JT, et al. Adalimumab for Ocular Inflammation. Ocul Immunol Inflamm. 2017 [Acceso 28/07/2021];25:405-12. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5033708/

  15. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology. 2014;21:785-96. DOI: https://doi.org/10.1016/j.ophtha.2013.09.048

  16. Fabiani C, Sota J, Sainz-de-la-Maza M, Pelegrín L, Emmi G, Lopalco G, et al. New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediat Inflamm. 2020 [Acceso 28/07/2021];8294560. Disponible en: https://www.hindawi.com/journals/mi/2020/8294560/

  17. Schuler S, Brunner M, Bernauer W. Rituximab and Acute Retinal Necrosis in a Patient with Scleromalacia and Rheumatoid Arthritis. Ocul Immunol Inflamm. 2016 [Acceso 28/07/2021];24:96-8. Disponible en: https://www.tandfonline.com/doi/full/10.3109/09273948.2014.999377

  18. Silpa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016 [Acceso 28/07/2021];94:e400-e6. Disponible en: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/aos.13015

  19. Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for Refractory Uveitis and Scleritis. Am J Ophthalmol. Case Rep. 2019 [Acceso 28/07/2021];13:53-5. Disponible en: https://www.sciencedirect.com/science/article/pii/S2451993618303402

  20. Pyare R, Kaushik V, Majumder PD, Biswas J. Tofacitinib in recalcitrant scleritis: First case report from India. Indian J Ophthalmol. 2020 [Acceso 28/07/2021];68:1988-90. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690527/

  21. Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel A, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) Gel. Drug Des Dev Ther. 2011 [Acceso 28/07/2021];5:147-53. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063118/

  22. Sohn EH, Wang R, Read R, Roufas A, Teo L, Moorthy R, et al. Long-Term, Multicenter Evaluation of Subconjunctival Injection of Triamcinolone for Non-Necrotizing, Noninfectious Anterior Scleritis. Ophthalmology. 2011 [Acceso 28/07/2021];118:1932-7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184362/

  23. Bhatt N, Dalal M, Tucker W, Obiyor D, Nussenblatt R, Sen HN. Subconjunctival Sirolimus in the Treatment of Autoimmune Non-Necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am J Ophthalmol. 2015 [Acceso 28/07/2021];159:601-6. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4329278/

  24. Turesson C, O'Fallon WM, Crowson CSM, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002 [Acceso 28/07/2021];29:62-7. Disponible en: https://www.jrheum.org/content/jrheum/29/1/62.full.pdf

  25. Kishore S, Maher L, Majithia V. Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace. Curr Rheumatol Rep. 2017 [Acceso 28/07/2021];19:39. Disponible en: https://link.springer.com/article/10.1007/s11926-017-0667-3

  26. Kempen JH, Pistilli M, Begum H, Fitzgerald TD, Liesegang TL, Payal A, et al. Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors. Am J Ophthalmol. 2019;24(3). DOI: https://doi.org/10.1016/j.ajo.2019.03.024




2020     |     www.medigraphic.com